# A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

Source: https://onco.cc/trials/nct03774056/  
OnCo record `nct03774056` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Deutenzalutamide run by Hinova Pharmaceuticals Inc., completed.

## Summary

A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. is a phase 1 interventional study registered as NCT03774056 by Hinova Pharmaceuticals Inc., with 43 participants enrolled, started 2017-02-10. Conditions recorded: Metastatic Castration Resistant Prostate Cancer. Interventions recorded: HC-1119.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03774056
- Phase: 1
- Setting: A Phase I Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients With Metastatic Castration-Resistant Prostate Cancer.
- Sponsor: Hinova Pharmaceuticals Inc.
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT03774056: https://clinicaltrials.gov/study/NCT03774056

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- drugs: [Deutenzalutamide](https://onco.cc/drugs/deutenzalutamide/)
- companies: [Hinova Pharmaceuticals](https://onco.cc/companies/hinova-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct03774056.json